Verona Pharma (VRNA) Projected to Post Earnings on Thursday

Verona Pharma (NASDAQ:VRNA) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Verona Pharma to post earnings of ($0.23) per share and revenue of $26.72 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Verona Pharma Trading Up 0.3 %

Verona Pharma stock opened at $64.19 on Friday. The stock has a market cap of $5.16 billion, a PE ratio of -33.43 and a beta of 0.41. The stock has a 50-day moving average price of $51.61 and a 200 day moving average price of $38.95. Verona Pharma has a 52 week low of $11.39 and a 52 week high of $65.50. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93.

Analyst Ratings Changes

A number of research firms recently commented on VRNA. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective (up previously from $42.00) on shares of Verona Pharma in a research report on Tuesday, January 21st. Canaccord Genuity Group lifted their price target on Verona Pharma from $44.00 to $72.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Roth Capital upgraded Verona Pharma to a “strong-buy” rating in a report on Friday, January 10th. Roth Mkm assumed coverage on Verona Pharma in a report on Friday, January 10th. They issued a “buy” rating and a $68.00 price target for the company. Finally, Wells Fargo & Company lifted their price target on Verona Pharma from $64.00 to $74.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $57.14.

Insider Transactions at Verona Pharma

In other news, CFO Mark W. Hahn sold 98,704 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $5.01, for a total transaction of $494,507.04. Following the completion of the sale, the chief financial officer now owns 14,177,296 shares in the company, valued at approximately $71,028,252.96. The trade was a 0.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kathleen A. Rickard sold 240,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $4.90, for a total value of $1,176,000.00. Following the transaction, the insider now directly owns 2,671,480 shares in the company, valued at $13,090,252. This trade represents a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 952,488 shares of company stock worth $4,743,881. 4.80% of the stock is currently owned by company insiders.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.